Mr. Marcos Agramont reports
ISODIOL INTERNATIONAL INC. COMMENCES PROCESS TO LIST ON THE AUSTRALIAN STOCK EXCHANGE
Isodiol International Inc. has initiated the process of obtaining a secondary listing on the Australian Securities Exchange and expects this process to be completed by the first quarter of 2018. The company has successfully completed the due diligence and corporate review requirements of the exchange and will now move forward in filing for approval.
In correlation with this dual listing, the company announces a strategic investment of $1-million at 25 cents with a full two-year warrant at 75 cents with a 30-day acceleration clause if the stock trades above $1 for 10 consecutive days. This capital will be used to finance the operational expansion into Australia and certain regions of Southeast Asia.
Marcos Agramont, chief executive officer of Isodiol International, stated: "We are excited to be expanding our footprint into Australia which we see as the gateway into Asia. We have seen incredible traction of our flagship product Isoderm in Latin America and we envision similar traction in the Australasia region. Obtaining a public listing on the ASX allows us to solidify our footprint, as well as access to the capital markets that a company would not have being based in Canada. This industry is in its infancy stage in Australia and we believe we can become the leaders in innovation and product development within the region. This listing will complement our current listings on the Canadian Stock Exchange (CSE), the OTC in the U.S. and Germany."
The company also announces August, 2017, unaudited revenue of its wholly owned subsidiary, Iso International LLC, of $1,410,743 (U.S.). Mr. Agramont stated, "As we continue to expand our operations into international markets, maintaining strong domestic revenues in North America has been a focus for us."
The company will provide additional information on its Australasia commercialization strategy as it is developed.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical- and nutraceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of a plus-99-per-cent-pure pharmaceutical-grade cannabinoid crystalline isolate derived from exempt parts of the hemp plant, microencapsulations, and nanotechnology for the highest-quality consumable and topical skin care products.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.